Cytokinetics (CYTK) R&D EVP exercises options and sells 3,500 shares

Rhea-AI Filing Summary

Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised stock options and sold shares in Cytokinetics Inc. On May 19, 2026, he exercised options for 3,500 shares of common stock at $7.80 per share and then executed an open-market sale of 3,500 shares at an average price of $75.69 per share. After these transactions, he directly holds 153,902 shares of common stock and 47,886 non-qualified stock options, indicating the sale represents a small portion of his overall equity position.

Insights

Equity compensation and insider-trading analyst

Routine exercise-and-sell by Cytokinetics EVP with large remaining stake.

EVP of Research & Development Fady Ibraham Malik exercised 3,500 non-qualified stock options at $7.80 and sold the same number of shares at $75.69 on May 19, 2026. This is a classic exercise-and-sell pattern converting options into cash.

Following the transactions, he still holds 153,902 common shares and 47,886 options. Because the sale is small relative to his remaining position, it looks like a routine liquidity event rather than a major shift in exposure based on this filing alone.

Insider Trade Summary 10b5-1

Net Seller: 3,500 shares ($264,915)

Net Sell 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 3,500 shs ($265K)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	--
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$75.69	$265K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 47,886 shares (Direct, null); Common Stock — 157,402 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 3,500 shares Sale price: $75.69 per share Option exercise price: $7.80 per share +2 more

5 metrics

Shares sold 3,500 shares Open-market sale of common stock on May 19, 2026

Sale price $75.69 per share Average price for 3,500 common shares sold

Option exercise price $7.80 per share Exercise price for 3,500 non-qualified stock options

Shares held after transaction 153,902 shares Direct common stock ownership following May 19, 2026 trades

Options remaining 47,886 options Non-qualified stock options outstanding after the exercise

Key Terms

Non-Qualified Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, derivative security

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		M		3,500	A	$7.8	157,402	D
Common Stock	05/19/2026		S		3,500	D	$75.69	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$7.8	05/19/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	47,886	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cytokinetics (CYTK) EVP Fady Malik report?

He reported exercising options and selling shares. On May 19, 2026, he exercised 3,500 non-qualified stock options at $7.80 and sold 3,500 Cytokinetics common shares in an open-market transaction at an average price of $75.69 per share.

How many Cytokinetics (CYTK) shares did the EVP sell and at what price?

He sold 3,500 common shares. The sale was an open-market transaction at an average price of $75.69 per share, as disclosed in the Form 4, and was matched to the same number of shares acquired through an option exercise.

What options did the Cytokinetics EVP exercise in this Form 4 filing?

He exercised 3,500 non-qualified stock options. These options carried a conversion or exercise price of $7.80 per share, were originally exercisable from March 27, 2018, and had an expiration date of February 27, 2028, with common stock as the underlying security.

How many Cytokinetics (CYTK) shares does the EVP hold after the transactions?

After the reported transactions, he directly owns 153,902 shares of Cytokinetics common stock. This figure reflects his position following the 3,500-share option exercise and the matching 3,500-share open-market sale reported for May 19, 2026.

What derivative holdings remain for the Cytokinetics EVP after this Form 4?

He retains 47,886 non-qualified stock options. These remaining options are shown as derivative securities following the exercise of 3,500 options, indicating a continued significant derivative-based exposure to Cytokinetics common stock after the reported transactions.

Is the Cytokinetics EVP transaction primarily a buy or sell event?

Net, it is a small sell event. He exercised 3,500 options to acquire shares, then sold 3,500 shares, resulting in net-sell shares of 3,500 according to the transaction summary, while maintaining a substantial ongoing equity and option position.